Amination
Introduction
The topoisomerases are ubiquitous enzymes essential for the vital cellular processes as involved in different steps of DNA replication, transcription, recombination and several reviews describe their characteristics and their activity on DNA in cells [1, 2, 3, 4] . In particular topoisomerase I and topoisomerase II play a key role binding to the DNA double helix inducing temporary single (Topo I) or double strand break (Topo II) allowing relaxation of the DNA for replication. Then the inhibition of these enzymes is lethal and leads to cell death, thus establishing Topo I and II as promising targets for cancer treatment and as a goal for the development of a new class of anticancer drugs. all the instability under physiological conditions have encouraged the development of new CPT analogues and non-CPT topo I inhibitors. The interest in topoisomerase I as a therapeutic target promoted various efforts to identify other chemotypes effective as topoisomerase inhibitors and chemical/modelling efforts to rationally design specific analogs among known inhibitors [8, 9, 10, 11] . During the last years several tetra-and pentacyclic structures containing the indoline fragment has received much attention due to the structural correlation with natural compounds belonging to the alkaloids class endowed with biological activity as cyclooxygenase/5-lipooxygenase inhibitors, characterized by the presence of the pyrrolo [3,2-de] acridine subunit [12] , indolocarbazoles non-CPT topo I inhibitors [13, 14, 15, 16] and analogues of physostigmine alkaloids [17, 18, 19, 20] .
Fig. 1. Topo I inhibitor compounds
Having topoisomerase I as biological target, our efforts were addressed to realize new heteropolycyclic structure based on scaffold hopping combining some of the structural features of 5-lipooxygenase inhibitors, physostigmine derivatives and CPT derivatives. The following key step consisted in the Pd-catalyzed N-arylation of the derivatives 3 with 2-chloroquinoline-3-carbaldehydes 4, affording the products 5. (Scheme 4) The reaction conditions were optimized as showed in Table 1 , the best conditions used the Pd2(dba)3 as catalyst and triisobutylphosphatrane (IAPU) as ligand, in toluene at 110 °C, in the presence of t-BuONa as base. The reaction required the protection of the formyl substituent as acetal. (Table 1, The subsequent step was the intramolecular Friedel-Craft reaction of the intermediate 5 using the protected formyl group directly [23] . The polyheterocyclic alkylated derivative was obtained as a mixture of two products 6 and 7, one of which was the oxidized form of the alkylated product 6. (Scheme 5) The treatment of the mixture with oxidants MnO2 and mCPBA resulted in the complete transformation of compound 6 in 7.
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LA REVUE GESTION ET ORGANISATION 00 (2013) 000-000 4 Scheme 5. Reagents and conditions: (i) BF3-Et2O (3-5 eq), CH2Cl2, 0 °C, 10 min, rt, 48h; (ii) MnO2 (4 eq), m-CPBA (5 mol%), THF/H20 (4:1), 60 °C, 12h, 50-80%.
The insertion of different substituents on the polycyclic scaffold 7 has been realized with the aim to evaluate changes in the biological activity, in fact the presence of polar groups may have strong interaction with the enzyme. The functionalization in position 1 may be obtained from 7 by reduction of the carbomethoxy group to give compound 8 or by hydrolysis obtaining derivatives 9a-d. (Scheme 6) Scheme 6. Reagents and conditions: (i) Red-Al ® (10 eq), toluene, 0 °C, 10 min, 110 °C, 5h, 50%; (ii) NaOH (15 eq), EtOH/H2O (3:1), 80 °C, 5-8h, 65-85%; (iii) BBr3 (2.5 eq), CH2Cl2, 40 °C, 24-48h, 70-80%.
The methoxy substituents may be present in positions 5 and 10, the reaction with BBr3 of the intermediates 9 resulted in the formation of the phenolic derivatives 10. The 2-hydroxyethyl substituent selected as polar branch, was formed in position 3a from the allyl susbstituent of the compound 7b, through the sequence oxidation-reduction affording the compounds 12 and 13. (Scheme 7) Scheme 7. Reagents and conditions: (i) OsO4 (4 mol%), NaIO4 (3 eq), lutidine (2 eq), THF/H2O The Figure 2 and Table 2 showed as convenience the sum of the different substituents on compounds 7-17 evaluated for their antiproliferative activity. 3.3. Effect on topoisomerase. DNA topoisomerase I has been shown to be the target of many anticancer agents, both camptothecin (topotecan and irinotecan) and non-camptothecin (indolocarbazoles and phenanthroline) derivatives [2, 3] . From a mechanistic point of view, agents that inhibit topoisomerase I can be grouped into two classes: poisons and suppressors. [25, 26] .
Fig. 2. Different substituents on the hexacyclic scaffold
In this connection and based on the above results, we investigate the ability of the most active derivative 13 and of the structurally related 9b, to affect the catalytic activity of topoisomerase I. Figure Therefore, to discriminate between a specific poisoning action and other possible nonspecific effects, due for example to DNA intercalation, the experiments were performed with agarose gel containing ethidium bromide and the results are showed in Figure 5 , in comparison with CPT.
Indeed, in these latter experimental conditions the DNA species moving toward the anode become progressively saturated by the intercalative effect of ethidium and this influences significantly their rate of migration.
Otherwise, the electrophoretic mobility of the band corresponding to the nicked DNA, resulting from the stabilization of the cleavable complex, is unaffected by the presence of ethidium bromide and thus can be easily detected [27] . LA REVUE GESTION ET ORGANISATION 00 (2013) 000-000 8 0.5 µM concentration. It is interestingly to note that these results are in agreement with cytotoxicity data reported in Table 3 . Indeed, 13
demonstrates an antiproliferative effect clearly higher with respect to 9b, with GI50 values from 4 to 11 times lower, depending on the cell line taken into consideration. As regard CPT, its cytotoxicity is notably higher with respect to both new derivatives and indeed GI50 even in the nanomolar range are obtained (Table 3) . Thus, it can be concluded that a correlation can be drawn between the poisoning effect and the antiproliferative ability.
Analysis of the binding mode
The binding mode of the most interesting compounds 13 and 9b was analyzed by docking calculations and compared to that of the reference crystallographic compound topotecan ( Fig. 6 ).
.
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Fig. 6. Panel A: Predicted binding mode for compounds 13 (carbon atoms coloured in magenta) and 9b (carbon atoms coloured in orange). The crystallographic structure of topotecan (PDB code: 1K4T; carbon atoms coloured in green) is also reported as a reference. Panels B, C and D: diagram reporting all ligand interactions for topotecan and compounds 9b and 13, respectively.
The docked conformation of reference compound topotecan is in excellent accord with the crystallographic structure (see Fig. S54 , Supporting Information), providing support to the following discussion. Moreover, the binding energies computed for topotecan, 9b and 13 are -129.4, 128.2 and -128.4 kcal/mol, respectively, thus the docking software correctly ranks the three compounds. The binding mode predicted for 9b and 13 ( Fig.6 , panels A, C and D) shows that the tetracyclic planar moiety is in both cases well packed inbetween the two DNA bases pairs made by deoxycytidine 599 and deoxyguanosine 576 (corresponding to the 5' terminus of the cleaved DNA strand) and by deoxyadenosine 600 and thymidine 575, which is covalently bound to Tyr523 through its 3' phosphate group. The benzonaphthyridinone group of 9b and 13 (rings A-C, Fig. 2 ) are partially overlaid with the pyrroloquinoline group of topotecan (rings A-C, Fig. 1 and Fig. 6 , panels A and B), with the scaffold of the former compounds being slightly shifted toward the α-helix formed by residues Thr518-Tyr523. This shift allows compounds 9b and 13 to form a moderately strong H-bond involving the nitrogen atom of ring B and the guanidine group of Arg164 (N···H distance = 2.47 and 2.42 Å; N···H-N angle = 169.0 and 170.8 deg. for compounds 9b and 13, respectively) [28] . The difference in antiproliferative activity (Table 3 ) and in topoisomerase I poisoning (Figs. 4 and 5) observed for compounds 9b and 13 are reasonably due to the substituent at C-3a. Indeed, the allyl chain of 9b is not apparently involved in any interaction with either topoisomerase or DNA. Conversely, a rather strong H-bond is observed between the hydroxyethyl substituent and the acidic group of Asp333 (H···O=C distance = 1.65 Å; O-H···O=C angle = 175.5 deg.).
Conclusion
We describes the preparation of a new scaffold starting from triptamines exploiting as a key step the sequential protocol Pd-catalyzed N-
The antiproliferative activity of the derivatives due to the topoisomerase I inhibition has been evaluated. Although the potency of the new derivatives is two orders of magnitude lower than that of CPT, all compounds resulted active on at least two of the three evaluated cell lines.
A computational binding mode analysis has thus been performed on compound 13 to provide insights possibly useful for designing decorations that might improve the activity of the scaffold here described. 
Experimental section

Synthesis of methyl (2-(indol-3-yl)ethyl)carbamates 2.
The products 2a [29] (yield 85%) and 2b [30] (yield 91%) were synthesized following the procedure reported in literature [30] .
Synthesis of tetrahydropyrrolindoles 3.
To a solution of Pd(PPh3)4 (0.005 mmol) in THF (5 ml The products 4a [31] (yield 98%) and 4b [31] (yield 99%) were synthesized following the procedure reported in literature [31] .
General procedure for N-arylation of tetrahydropyrrolindoles 3.
To a solution of Pd2(dba)3 (0.02 mmol) and triisobutylphosphatrane (0.08 mmol) in toluene (25 ml To a solution of compound 7d (1 mmol) in toluene (10 ml To a solution of compound 9 (1 mmol) in CH2Cl2 (10 ml [2',3':2,3] indolo [1,7-ab] [1, 8] [2',3':2,3] indolo [1,7-ab] [1, 8] naphthyridin-1ium bromide (14) .
To a solution of compound 13 (1 mmol) in CH2Cl2 (10 ml), cooled at -78 °C, was added dropwise BBr3 (1M in Hexane, 2.5 mmol). After 1 h at rt the mixture was warmed at 40 °C for 12 h. Then the reaction mixture was poured over ice and the organic layer was separated, dried over Na2SO4
and concentrated under vacuum. The crude product was used directly for the subsequent reaction without purification.
10-Hydroxy-3a-(2-hydroxyethyl)-7-oxo- 1,2,3,3a,7,14atetrahydrobenzo[g] pyrrolo [2',3':2,3] indolo [1,7-ab] [1, 8] naphthyridin-1ium bromide (14) . Yield: 50%. Red solid. 255-256 °C (CH2Cl2/AcOEt). tert-Butyl 3a-allyl-10-hydroxy-7-oxo-3,3a,7,14atetrahydrobenzo[g]pyrrolo [2',3':2,3] indolo [1,7-ab] [1, 8] 
Computational analysis.
The structure of the receptor was obtained from the crystal structure of the topoisomeraseI-DNA-topotecan ternary complex (PDB code: 1K4T) and prepared as previously described [32] . Docking calculations were performed with the software PLANTS [33] . The search space was defined by using the crystallographic ligand center of mass coordinates as the binding site center (x = 49.3764, y = 46.9081 and z = 48.2818) and the binding site radius was set to 14 Å, corresponding to the ligand radius of gyration augmented by 6 Å. Maximum accuracy was requested by setting the search_speed parameters to "speed1". All the other parameters were used as default. Ligands were prepared using MOE 2015 [34] , and processed by M A N U S C R I P T
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SPORES in order to assign the correct atom types required for docking calculations with PLANTS [35] . By using this setup, the overlay between the lowest energy docked conformation of topotecan (binding energy = -129.4 kcal/mol, computed with the CHEMPLP scoring function) [36] and its crystallographic structure was excellent, with a RMSD of 1.52 Å, computed with VMD 1.9.1 [37] . 
